Asterand UK Limited

Corcept Therapeutics Incorporated

Helperby Therapeutics Limited

Antabio Sas

Janssen Pharmaceutica Nv

Zafgen, Inc.

Kalvista Pharmaceuticals Limited

Pharmagene Laboratories Limited

David Edward Clark

George Hynd

Jonathan Mark Sutton

Alexander W Oxford

Kenneth Lyle Clark

Garry Fenton

Robert Alexander Coleman

Richard Jon Davis

Neil Victor Harris

Thomas David Pallin

Keith Alfred James Stuttle

Hazel Joan Dyke

Robin D Clark

Edward Andrew Boyd

Karen Williams

Mark Richard Ashton

Shirley Ann Brunton

Keith A J Stuttle

Christopher G Newton

Marc Barry Brown

Richard Leonard Elliott

Yanmin Hu

Toby Jonathan Blench

Derek John Londesbrough

Anthony Coates

David Thomas Davies

Simon Leiris

Gary Patrick Reid

Martin Everett

Nicolas Sprynski

Petra Helga Beck

Gerlinda Stoddart

Andrew Peter Cridland

Lilha Beyria

Keith Mills

Robert Zahler

Janusz Jozef Kulagowski

John Gary Montana

Hazel Joan Hunt

Stephen Colin Price

Nicholas Charles Ray

Christopher Hurley

Calum MacLeod

Susan Mary Cramp

Samuel Edward Mann

Patrizia Tisselli

Paul M Blaney

Nicolas C Ray

Peter H Crackett

Gwen Hickin

David Michael Evans

Nadia M Ahmad

Emanuela Gancia

Hannah Joy Edwards

Rebecca Louise Davie

Terry Aaron Panchal

Michael D Ryan

Thomas Matthew Baker

Simon Teanby Hodgson

Alun John Smith

Toby Matthew Grover Mullins

Michael John Stocks

Fabien Jean Ghislain Roussel

Michael Steven Bodnarchuk

Alessandro Mazzacani

Matthew Robert Conroy

The invention relates to an indane compound according to Formula (I), or a pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, L, n and p are as defined herein. The compounds are useful for treating antibacterial infection either as stand-alone antibiotics, or in combination with further antibiotics.

Indane derivatives for use in the treatment of bacterial infection

The invention provides aza-heterocyclyl carboxamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as bacterial infections, and in inhibiting LpxC activity.

Aza-heterocyclyl carboxamide and related compounds and their use in treating medical conditions

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.

Enzyme inhibitors

The invention relates to a compound which is an indane derivative according to Formula (I), or a pharmaceutically acceptable salt thereof, [FORMULA (I)] wherein R, R, R, n, R, p, q, L, X and m are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics. The compounds can also be used in vitro, for example in cleaning compositions. 

Chemical compounds as antibiotics

There is provided the use of compounds of formula I wherein R, R, Rand X have meanings given in the description, for the preparation of a medicament for killing clinically latent microorganisms. There is also provided the use of compounds of formula I for treating microbial infections, as well as certain compounds of formula I per se.

Use of pyrroloquinoline compounds to kill clinically latent microorganisms

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-&#x3ba;B-inducing kinase (NIK&#x2014;also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

[object Object]

The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

Tricyclic compounds and methods of making and using same

The present invention provides a novel class of azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.

Azadecalin glucocorticoid receptor modulators

The present invention provides a class of modified pyrimidine compounds, compositions and methods of using the compounds as glucocorticoid receptor modulators.

Modified pyrimidine glucocorticoid receptor modulators

A compound of formula (III): or a salt, solvate and chemically protected form thereof, wherein: Ris an optionally substituted Caryl or Calkyl group; L' is a single bond, &#x2014;O&#x2014; or &#x2014;C(&#x2550;O)&#x2014;; A is selected from the group consisting of: formula (i) (ii) (iii) wherein X and Y are selected from the group consisting of: O and CR; S and CR; NH and CR; NH and N; O and N; S and N; N and S; and N and O, and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; D is selected from: formula (i) (ii) (iii) (iv) (v) (vii) (viii) (ix) B is selected from the group consisting of: formula (A) (B) where Ris selected from fluoro and chloro; and Ris either: (i) &#x2014;COH; (ii) &#x2014;CONH; (iii) &#x2014;CH&#x2014;OH; or (iv) tetrazol-5-yl. 

Growing community of inventors

Essex, United Kingdom

David Edward Clark